Elderly non-small cell lung cancer patients undergoing definitive radiation have a lower incidence of esophagitis compared to younger patients and tolerate aggressive standard treatment regimens. Lung cancer is the leading cause of cancer deaths worldwide, causing more deaths than breast, colon, and prostate cancers combined.
Category: Oncology
Defects in key gene spur breast and ovarian cancer growth, study shows
Defects in a key gene – long thought to drive cancer by turning off the protection afforded by the well-known BRCA genes – spur cancer growth on their own, according to a study led by researchers from NYU Langone Medical Center. The study gene, known as EMSY, has some of the same functions as BRCA1 and BRCA2, which are known to protect against breast and ovarian cancer when normal.
Old Cancer Drug Gets 1,000%-Plus Price Hike in Frugal U.K.
… isn’t the only medicine whose price has unexpectedly surged in one of the world’s most tightly-controlled markets for health spending. Melphalan, a chemotherapy in use for ovarian cancer since the 1950s, had a 315 percent cost increase in the same …
Global Breast Health & Wellness Center Expands Use of Cryoablation…
Dr. April L. Speed, first in Georgia to provide cryoablation for early stage breast cancer with the Visica 2 Treatment System Global Breast Health & Wellness Center, founded by Dr. April Speed, announced it has expanded its cryoablation treatment of fibroadenoma to include early stage breast cancer with the Visica 2 Treatment System. Developed by Sanarus Technologies, the Visica 2 Treatment System is a cryoablation device that uses extreme cold liquid nitrogen to destroy tissue .
Novartis Signals Growing Ambitions for CAR-T Cancer Treatments
Novartis AG is pushing ahead with one of its most ambitious cancer therapies, a treatment that the Swiss drugmaker says has blockbuster potential as it extends that technology to a wider pool of tumor-ridden patients. Europe’s second-biggest drugmaker is planning to test its CAR-T treatments — which involve extracting immune cells and genetically engineering them to hunt and kill cancer cells before returning them into the patient’s body — on lethal cancers of the brain, pancreas, colon, ovary and lung.
New immunotherapy active against mucosal melanoma and improves survival for bladder cancer patients
Clinical trials of a new immunotherapy, pembrolizumab, have shown that it prolongs life significantly for patients with bladder cancer and is active against a rare sub-type of melanoma, called mucosal melanoma. The findings were presented in two presentations at the European Cancer Congress 2017 today .
3 Biotech Stocks I’d Buy Right Now
Despite the sway of political uncertainty for the biotechnology industry at the moment, these three stocks look like great buys right now. Conflicting statements from the Trump administration have made owning biotech stocks feel like a roller-coaster ride in recent weeks, but there are a few stocks I’d happily buy and hold despite the sway of political uncertainty.
California Gov. Jerry Brown will undergo further radiation treatment for prostate cancer.
California Gov. Jerry Brown will undergo further radiation treatment for prostate cancer first treated in 2012, his office announced Saturday. Brown’s oncologist, Dr. Eric Small of the University of California, San Francisco, said the cancer is not extensive and can be treated with “a short course of radiotherapy.”
Governor Brown to Get Further Prostate Cancer Treatment
Brown’s oncologist, Dr. Eric Small of the University of California, San Francisco, says in the statement the disease is not extensive and can be treated with “a short course of radiotherapy.” Brown’s office says he will continue his full work schedule through treatment, which is planned to occur between late February and early March.
Governor Brown to Get Further Prostate Cancer Treatment
Brown’s oncologist, Dr. Eric Small of the University of California, San Francisco, says in the statement the disease is not extensive and can be treated with “a short course of radiotherapy.” Brown’s office says he will continue his full work schedule through treatment, which is planned to occur between late February and early March.
Study shows evidence that intestinal microorganisms can serve as link …
… of certain types of colorectal cancer,” said Shuji Ogino, MD, PhD, of Dana-Farber, Harvard T.H. Chan School of Public Health, and Brigham and Women’s Hospital, the co-senior author of the study with Charles Fuchs, MD, MPH, director of the …
Johnson & Johnson’s Most Exciting Opportunity
Can cancer drug sales continue to soar? Here’s why cancer drugs could be Johnson & Johnson’s most exciting opportunity in 2017. Global spending on cancer drugs eclipsed $100 billion two years ago, and aging and longer-living populations worldwide have IMS Health projecting that global spending on cancer medicine could hit $150 billion in 2020.
Erin Andrews reveals battle with cervical cancer and how she didn’t let it send her to the sidelines
Erin Andrews has won another battle, this time out of court. In 2016, after settling her $55 million lawsuit with a Nashville Marriott, the Dancing with the Stars co-host also battled cervical cancer .
Chemo Overused in Younger Colon Cancer Patients?
… trend of younger patients being diagnosed with colon cancer,” said Dr. Anna Levy. She’s an oncologist at Northwell Health Cancer Institute in Lake Success, N.Y. “The premise for the paper is a valid one,” she added. “When faced with a fit, young …
Heat Biologics to Present at NobleCon13
Heat Biologics, Inc. , a leader in the development of immunotherapies designed to activate a patienti 1 2s immune system against cancer, announced that Jeff Wolf, Heati 1 2s Chief Executive Officer, will present at the NobleCon13 i 1 2 Noble Capital Marketsi 1 2 Thirteenth Annual Investor Conference at the Boca Raton Resort & Club in Boca Raton, Florida on Tuesday, January 31, 2017, at 10 a.m. Eastern Standard Time. The link to the live audio webcast and replay of the presentation may be accessed on Heati 1 2s corporate website at .
Heat Biologics to Present at NobleCon13
Heat Biologics, Inc. , a leader in the development of immunotherapies designed to activate a patienti 1 2s immune system against cancer, announced that Jeff Wolf, Heati 1 2s Chief Executive Officer, will present at the NobleCon13 i 1 2 Noble Capital Marketsi 1 2 Thirteenth Annual Investor Conference at the Boca Raton Resort & Club in Boca Raton, Florida on Tuesday, January 31, 2017, at 10 a.m. Eastern Standard Time. The link to the live audio webcast and replay of the presentation may be accessed on Heati 1 2s corporate website at .
3 Stocks Dominating the Future of Healthcare
The healthcare sector is undergoing a revolution of sorts due to the advent of several game-changing new technologies, medical devices, and pharmaceutical products. To help investors get a grasp on this technologically fueled shift in healthcare, we asked three of our contributors to discuss which changes they think are the most critical to watch right now.
3 Stocks Dominating the Future of Healthcare
The healthcare sector is undergoing a revolution of sorts due to the advent of several game-changing new technologies, medical devices, and pharmaceutical products. To help investors get a grasp on this technologically fueled shift in healthcare, we asked three of our contributors to discuss which changes they think are the most critical to watch right now.
DRP successfully predicts effect of 4 Breast Cancer drugs for Personalized Medicine
Hoersholm, Denmark, January 24 th , 2017 – Medical Prognosis Institute A/S today announced that its Drug Response Predictor DRP tool was studied as a tool for Personalized Medicine – Patient Response Prediction – PRP . MPI’s vision is to develop a tool in the form of a report over drugs that are most likely to be effective for the individual cancer patient.
Leap Therapeutics and Macrocure Complete Merger Transaction
Leap Therapeutics, Inc. , a biotechnology company developing targeted and immuno-oncology therapeutics, today announced the completion of its merger with Macrocure Ltd , with Macrocure becoming a wholly-owned subsidiary of Leap. Leap will be listed on The Nasdaq Global Market under the symbol “LPTX” and expects to begin trading on Tuesday, January 24, 2017.
Many With Advanced Lung Cancer Don’t Get Treatments That Might Help
Many U.S. patients with late-stage lung cancer do not receive treatments that could prolong their lives, a new study finds. Researchers at the University of California, Davis Comprehensive Cancer Center analyzed 1998-2012 data from the U.S. National Cancer Database.
3 Biotechs Likely to Be Acquired in 2017
The year is still young, but we’ve already seen acquisitions of Ariad and CoLucid . Which biotechs could be scooped up next in 2017? Here’s why Clovis Oncology The number of big companies battling to acquire Medivationin 2016 shows that the oncology space is hot.
Surrey Prostate Cancer Support Group hosts meeting Jan. 28
The organization holds supportive gatherings on the last Saturday of every month for men affected by prostate cancer and provides awareness, public education, advocacy, support and research into the prevention, detection, treatment and cure of prostate cancer. On Jan. 28, Dr. Michael Peacock from UBC Radiation Oncology will speak on Prostate Brachytherapy treatments and effects.
Therapeutic Apheresis & Donor Apheresis Market Global Analysis 2024
… and Opportunities The growth of the global apheresis market can be attributed to the growing awareness regarding good health among consumers worldwide. The rising concerns among consumers regarding the prevalence several anomalies have impelled them …
Why Bristol-Myers Squibb Co Stock Is Slipping Today
An announcement that it won’t seek accelerated approval for a combination lung cancer therapy comprised of two key drugs isn’t sitting well with the market in light of Merck & Co. ‘s Lung cancer might not be the most common malignancy, but it is the deadliest.
Recent Analysts’ Ratings Changes for Aeterna Zentaris
… biopharmaceutical company engaged in developing and commercializing treatments in oncology, endocrinology and women’s health. The Company operates through the biopharmaceutical segment. The Company is engaged in drug development activities and in …
Researchers find elephant protein destroys human cancer cells
Inside a petri dish, Doctor Joshua Schiffman shows us how a synthetic elephant protein, “We’ve made it in a lab. We’ve introduced it into these cells,” actually attacks human cancer cells as highlighted by the glowing green.
“Top 15” List Predicts Best-Selling Cancer Drugs in 2022
FiercePharma has compiled a list of the top 15 cancer medications that are expected to dominate the oncology market in 2022. According to the report, oncology drugs remain the fastest-growing category in pharma, with anticipated sales of approximately $90 billion over the next five years.
Know the Risks, Warning Signs of Ovarian Cancer
Women need to be aware their risk for ovarian cancer increases with age. Half of all cases affect women age 63 or older, according to specialists at Fox Chase Cancer Center in Philadelphia.
Press release distribution, EDGAR filing, XBRL, regulatory filings
… of Payroll Expenses Reveals )–The JPMorgan Chase Institute released its newest report today on the financial health of small businesses and employment challenges they continue to face. The first-of-… )–Aviatrix Systems, a pioneer in hybrid cloud …
Common Heart Drug Repurposed to Treat Rare Cancer in Europe
… blood pressure, is being repurposed to treat soft tissue sarcomas. Credit: Tommie Morelos / Texas Tech University Health Sciences Center El Paso. Click here for high-resolution version Brad Bryan, Ph.D., a biomedical scientist at Texas Tech …
Cancer patientsa distress over drug access
Terminal breast cancer patients have spoken of their distress after learning that a life-extending drug they had been told would be available to them looks set to be withdrawn. Advisory body NICE is reviewing drugs made available through the old cancer drugs fund, and has rejected Kadcyla for use on the NHS in England.
Family of Wayne Co. baby who passed away speaks about loss
Vaida Scott passed away earlier in the week from RSV. She was one of the youngest ever to be diagnosed with Myelomonocytic Leukemia, a rare form of bone cancer.
French Mesothelioma Researchers Find Prognostic Promise in BAP1, According to Surviving Mesothelioma
A better overall survival was observed for patients with BAP1 mutations, protein expression loss, or at least one of these alterations… Doctors at multiple French cancer centers have just published research on the relationship between the BAP1 gene and peritoneal mesothelioma survival. Surviving Mesothelioma has posted the details of the new research.
French Mesothelioma Researchers Find Prognostic Promise in BAP1, According to Surviving Mesothelioma
A better overall survival was observed for patients with BAP1 mutations, protein expression loss, or at least one of these alterations… Doctors at multiple French cancer centers have just published research on the relationship between the BAP1 gene and peritoneal mesothelioma survival. Surviving Mesothelioma has posted the details of the new research.
Technology and cost barriers hinder real-time reporting of cancer patients’ symptoms
Capturing real-time reports of cancer patients’ symptoms between doctor’s visits has proven health benefits, but technology and cost barriers are getting in the way of widespread adoption of the practice, reports a University of North Carolina Lineberger Comprehensive Cancer Center researcher. In a perspective published in the New England Journal of Medicine, Ethan Basch, MD, MSc, addressed the need for – and the barriers preventing – electronic reporting of patients’ symptoms between visits.
Cost, technology issues are barriers to real-time cancer patient symptom reporting
Capturing real-time reports of cancer patients’ symptoms between doctor’s visits has proven health benefits, but technology and cost barriers are getting in the way of widespread adoption of the practice, reports a University of North Carolina Lineberger Comprehensive Cancer Center researcher. In a perspective published in the New England Journal of Medicine , Ethan Basch, MD, MSc, addressed the need for – and the barriers preventing – electronic reporting of patients’ symptoms between visits.
Diluted chemo drug victims ask judge to reject settlement they call a slap in the face
… negligence by everyone involved,” said Omstead-Mullins, a Ford worker who criticized the lack of quality control in health care. One of the vocal opponents of the settlement, mother of three Sarah Johnson, 41, was unable to attend Tuesday’s court …
Cleveland Clinic doc pens viral screed against vaccines, peers call it ‘post-truth medicine’
… Freedhoff . “Wow, this quack is the head of an institute of an actual medical center?” added Vinay Prasad, an Oregon Health and Sciences University oncologist. The Cleveland Clinic is not just any medical center. It is renowned, particularly in the …
Survivor of the Year
Newly named the Komen VT-NH Affiliate’s Survivor of the Year for 2007, Kerry Clifford, of Brandon, has competed in the Komen Race for the Cure held at Hildene Meadows in Manchester for ten out of the past 11 years. She has consistently finished in the 5K Walk’s Overall Top 35, with her best Overall Walker finish in 7th place in 1999 and finished the 5K Walk as one of the top-4 breast cancer survivors in all ten Komen races she has taken part in.